Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmar C Lehmann

Showing results (11-20 of 146) with videos related to

Pageof 15
Sort By:
Journal of Neurology|July 28, 2009
Variants of Guillain-Barré syndrome: low incidence but high impactHelmar C Lehmann, Hans-Peter Hartung
Fortschritte Der Neurologie-Psychiatrie|July 10, 2024
[Correction: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)]Barbara Kaulen, Laura Hagemann, Helmar C Lehmann
Current Pharmaceutical Design|March 27, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future ApproachesMartin K R Svačina, Helmar C Lehmann
Fortschritte Der Neurologie-Psychiatrie|June 14, 2024
[Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)]Barbara Kaulen, Laura Hagemann, Helmar C Lehmann
Journal of Clinical Immunology|September 8, 2012
Negative regulators of schwann cell differentiation-novel targets for peripheral nerve therapies?André Heinen, Helmar C Lehmann, Patrick Küry
Journal of Neuroinflammation|August 14, 2015
Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulinsChristian Ritter, Ilja Bobylev, Helmar C Lehmann
Lancet (London, England)|March 1, 2021
Guillain-Barré syndromeNortina Shahrizaila, Helmar C Lehmann, Satoshi Kuwabara
Experimental Neurology|December 9, 2019
Modeling chemotherapy induced peripheral neuropathy (CIPN) in vitro: Prospects and limitationsHelmar C Lehmann, Nathan P Staff, Ahmet Hoke
Neurology|May 30, 2018
150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacyHelmar C Lehmann, Alastair Compston, Hans-Peter Hartung
Therapeutic Advances in Neurological Disorders|January 9, 2023
Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?Felix Kohle, Marinos C Dalakas, Helmar C Lehmann
Pageof 15

Showing results (11-20 of 146) with videos related to

Sort By:
Pageof 15
Journal of Neurology|July 28, 2009
Variants of Guillain-Barré syndrome: low incidence but high impactHelmar C Lehmann, Hans-Peter Hartung
Fortschritte Der Neurologie-Psychiatrie|July 10, 2024
[Correction: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)]Barbara Kaulen, Laura Hagemann, Helmar C Lehmann
Current Pharmaceutical Design|March 27, 2022
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future ApproachesMartin K R Svačina, Helmar C Lehmann
Fortschritte Der Neurologie-Psychiatrie|June 14, 2024
[Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)]Barbara Kaulen, Laura Hagemann, Helmar C Lehmann
Journal of Clinical Immunology|September 8, 2012
Negative regulators of schwann cell differentiation-novel targets for peripheral nerve therapies?André Heinen, Helmar C Lehmann, Patrick Küry
Journal of Neuroinflammation|August 14, 2015
Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulinsChristian Ritter, Ilja Bobylev, Helmar C Lehmann
Lancet (London, England)|March 1, 2021
Guillain-Barré syndromeNortina Shahrizaila, Helmar C Lehmann, Satoshi Kuwabara
Experimental Neurology|December 9, 2019
Modeling chemotherapy induced peripheral neuropathy (CIPN) in vitro: Prospects and limitationsHelmar C Lehmann, Nathan P Staff, Ahmet Hoke
Neurology|May 30, 2018
150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacyHelmar C Lehmann, Alastair Compston, Hans-Peter Hartung
Therapeutic Advances in Neurological Disorders|January 9, 2023
Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?Felix Kohle, Marinos C Dalakas, Helmar C Lehmann
Pageof 15